^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Breast Cancer
    Drug:Zirabev (bevacizumab-bvzr) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    02/14/2019
    Excerpt:
    Zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer.
    Secondary therapy:
    paclitaxel